THNR ETF
Amplify Weight Loss Drug & Treatment ETF
THNR ETF Overview
THNR ETF (Amplify Weight Loss Drug & Treatment ETF) is managed by Amplify ETFs with $5.2M in net assets. THNR expense ratio is 0.59%, holding 23 positions across sectors including Health Care, Financials. Inception date: 2024-05-21.
THNR performance shows a YTD return of 2.09%. The 1-year return is 13.22%. THNR dividend yield stands at 1.59%, paid annually.
THNR top holdings include Eli Lilly & Co (11.1%), Novo-Nordisk A/S-Spons Adr (8.9%), Amgen Inc. (6.0%), Abbvie Inc. (5.7%), Roche Holding Ag- Genusschein (5.7%). Go to all THNR holdings, THNR sectors, or THNR dividends.
THNR can be compared against other funds. Use THNR overlap to find shared positions, or THNR vs another fund for a side-by-side view. THNR alternatives are available via the screener, along with tax-loss harvesting opportunities.